As of 11:36:33 AM EST. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | -- | 2 | 2 |
| Avg. Estimate | -0.13 | 0 | -1.27 | -0.94 |
| Low Estimate | -0.13 | 0 | -1.39 | -1.03 |
| High Estimate | -0.13 | 0 | -1.16 | -0.86 |
| Year Ago EPS | -0.2 | -- | -1.23 | -1.27 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 1 | 5 | 5 |
| Avg. Estimate | 204.8k | -- | 1.52M | 781.6k |
| Low Estimate | -- | -- | 1.3M | -- |
| High Estimate | 380k | -- | 1.7M | 1.59M |
| Year Ago Sales | 146k | 532k | 1.56M | 1.52M |
| Sales Growth (year/est) | 40.27% | -100.00% | -2.52% | -48.54% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.33 | -0.27 | -0.33 | -0.2 |
| EPS Actual | -0.2 | -0.35 | -0.26 | -0.14 |
| Difference | 0.13 | -0.08 | 0.07 | 0.07 |
| Surprise % | 40.76% | -30.60% | 21.04% | 32.44% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.13 | 0 | -1.27 | -0.94 |
| 7 Days Ago | -0.2 | 0 | -1.23 | -0.81 |
| 30 Days Ago | -0.2 | 0 | -1.23 | -0.81 |
| 60 Days Ago | -0.2 | 0 | -1.23 | -0.81 |
| 90 Days Ago | -0.2 | 0 | -1.23 | -0.81 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | -- | 1 |
| Up Last 30 Days | 1 | -- | -- | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| LYRA | 33.50% | -- | -3.95% | 25.88% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight | 8/15/2024 |
| Reiterates | HC Wainwright & Co.: Neutral to Neutral | 8/15/2024 |
| Reiterates | Cantor Fitzgerald: Overweight | 6/20/2024 |
| Downgrade | HC Wainwright & Co.: Buy to Neutral | 5/7/2024 |
| Downgrade | Jefferies: Buy to Hold | 5/7/2024 |
| Downgrade | BTIG: Buy to Neutral | 5/6/2024 |
Related Tickers
HLVX HilleVax, Inc.
2.1301
+2.90%
EPIX ESSA Pharma Inc.
1.8450
+3.07%
CLRB Cellectar Biosciences, Inc.
0.3150
+5.32%
ACHL Achilles Therapeutics plc
1.1450
+0.44%
ADTX Aditxt, Inc.
0.1982
+4.42%
IKNA Ikena Oncology, Inc.
1.6150
-1.52%
SPRO Spero Therapeutics, Inc.
1.0700
+3.88%
BOLT Bolt Biotherapeutics, Inc.
0.5430
+1.48%
CDT Conduit Pharmaceuticals Inc.
0.0718
+4.66%
CNSP CNS Pharmaceuticals, Inc.
0.1189
-1.25%